 |
인쇄하기
취소
|
Sanofi and Aventis likely to merge.
Leading French pharmaceutical companies,Aventis and Sanofi-Synthelabo are very likely to merge.
Chairman Jean-Francois Dehcq of Sanofi-Synthelabo indicated openly in an interview with Le Figaro on Jan. 9 about a merger possibility between two companies. He said ambiguously "We do not deny taking something to do with Aventis one day, but not sure now is the right time"
Mr. Dehecq added to ...
Chairman Jean-Francois Dehcq of Sanofi-Synthelabo indicated openly in an interview with Le Figaro on Jan. 9 about a merger possibility between two companies. He said ambiguously "We do not deny taking something to do with Aventis one day, but not sure now is the right time"
Mr. Dehecq added to ...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.